• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.
By JIM CRAMER Feb 22, 2017 | 11:45 AM EST
Stocks quotes in this article: BMY, MRK, LLY, AGN, JNJ, ABBV, REGN

Look, I totally get that Carl Icahn would take a big position in Bristol-Myers Squibb (BMY) and want to put it in play. But you know what you need before you do that?

A buyer.

Who would buy a $92 billion company that has just had its head handed to it by Merck (MRK) , with its cancer drug Keytruda over BMY's Opdivo? Who would buy this company knowing that 50% of its revenues go off patent in a few years, even as they throw off a lot of cash before they go? Maybe someone who could see the company as a biotech and decides that it's worth it to pay up for an established company, believing that Opdivo could be worth $70 to $100 billion.

We know that Pfizer took itself out of the running last quarter when it said it didn't want to do a big deal. Merck sure doesn't need them; it has Keytruda. Eli Lilly's (LLY) got tremendous momentum with its diabetes franchise. Action Alerts PLUS holding Allergan (AGN) has said it doesn't want to do a big deal. Johnson & Johnson (JNJ) just announced a monster deal -- so they aren't going to play.

That does leave AbbVie (ABBV) , which, I guess, is a possibility. But the dilution would be gigantic and AbbVie is focused on nearer-term earnings.

Europe? Sanofi wants to do a big deal, we know that. But I think they would buy Regeneron Pharmaceuticals  (REGN) . Your basically counting on GlaxoSmithkline, Novartis or Astra-Zeneca.

All of them know the issues, which is that Bristol-Myers stock is overvalued based on the current state of Opdivo -- with its only other major drug being Eliquis, which is terrific but not enough to drive the train.

Here's my bottom line: Bristol has had a tough time of late, no doubt about it. But it doesn't have to sell, and there sure aren't a lot of buyers.

Without one, I think this might be a very tough one to get into right now, based on Icahn alone -- and nothing else that I can see driving the acquisition.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Action Alerts PLUS, which Cramer co-manages as a charitable trust, was long AGN.

TAGS: Investing | U.S. Equity | Healthcare | Markets | Mergers and Acquisitions | Stocks

More from Healthcare

Bearish Bets: 3 Stocks You Should Consider Shorting This Week

Bob Lang
Jul 3, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:01 PM EDT PAUL PRICE

    A Recent Director Buy in Children's Place (PLCE)

    Four of the most recent insider trades in Children...
  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login